NeuroOne Medical Technologies Corporation (NMTC)

Next-Generation Platforms Scale Across Energy, Wellness, and Smokeless Consumer SegmentsMarch 5, 2026 9:00 AM
PR Newswire (US)

Issued on behalf of Doseology Sciences Inc.Equity-Insider.com VANCOUVER, BC, March 5, 2026 /PRNewswire/ -- Consumers are voting with their wallets, and zero-sugar is winning. Zero-sugar beverages are driving 6x more dollar growth than regular varieties as buyers actively choose clean-label products with natural sweeteners and functional ingredients[1]. The global market is forecast to expand from $350 billion in 2024 toward $500 billion by 2029, fueled by health-conscious consumers who want naturally functional products without heavy processing[1]. This structural shift is creating validated demand for precision-dosed, portable formats across energy and wellness categories, positioning Doseology Sciences (CSE: MOOD) (OTCPK: DOSEF) (FSE: VU70), Jamieson Wellness (TSX: JWEL), Herbalife (NYSE: HLF), USANA Health Sciences (NYSE: USNA), and Natural Health Trends (NASDAQ: NHTC).







The oral nicotine pouch segment is forecast to climb from $5.4 billion in 2024 to over $25 billion by 2030, a 29.6% annual growth rate that validates rising acceptance of pouch-based delivery systems[2]. Major consumer goods companies are integrating cognitive support and adaptogens into modern oral formats, targeting wellness alongside traditional energy delivery[3].Doseology Sciences (CSE: MOOD) (OTCPK: DOSEF) (FSE: VU70) just launched Feed That Brain Energy Pouches in the United States through a direct-to-consumer pilot program, marking the company's first DTC initiative in the U.S. market. Doseology specializes in pouch-based oral stimulant and cognitive support products. The rapidly expanding oral stimulant pouch sector is gaining momentum as consumers seek modern, discreet alternatives to traditional delivery formats. The pouches are now available exclusively to U.S. consumers at feedthatbrain.com and Amazon.com.The U.S. pilot represents a key milestone in Doseology's strategy to validate oral pouch delivery as a scalable stimulant platform, beginning with non-nicotine energy products. Unlike combustible tobacco or vape products, oral stimulant pouches are smokeless and vapor-free, providing an alternative delivery method without inhalation. The company will use this phase to evaluate consumer adoption, usage frequency, and repeat purchase behavior."This U.S. pilot is a disciplined and deliberate step in Doseology's strategy to build a scalable oral stimulant platform," said Larry Latowsky, Executive Chairman of Doseology. "Feed That Brain demonstrates how controlled, non-nicotine energy delivery can meet evolving consumer preferences while generating the operational insight required for responsible growth."Feed That Brain Energy Pouches are designed for modern, on-the-go use, offering consumers clarity and control without the volatility commonly associated with liquid energy formats. From a market perspective, the oral pouch category is experiencing strong global growth as consumers increasingly prioritize convenience, portability, and format innovation.The company also recently appointed Larry Latowsky as Executive Chairman, bringing experience from his tenure as President and CEO of Katz Group Canada, which operated over 1,500 pharmacy locations. Latowsky cited the clarity of Doseology's strategy and team quality as reasons for joining, stating confidence in building a durable platform and unlocking significant long-term value.Doseology also recently granted 140,000 restricted share units and 210,000 performance share units to a director, with RSUs vesting in equal monthly increments over 36 months and PSUs vesting upon achievement of defined performance milestones.Read this and more news for Doseology at: https://equity-insider.com/2025/12/19/what-comes-after-cigarettes-vapes-and-energy-drinks/In other industry developments and happenings in the market include:Jamieson Wellness (TSX: JWEL) recently reported full-year 2025 revenue of $822.1 million, a 13.4% increase driven by 15.6% branded revenue growth across Canada, China, and the United States. The company's Jamieson Brands segment led performance with broad-based strength in all markets, while Youtheory delivered 20.2% revenue growth through e-commerce innovation and expanded traditional distribution."2025 was an outstanding year for Jamieson Wellness, driven by sustained global demand for our products and superior execution across every key market," said Mike Pilato, President and CEO of Jamieson Wellness. "As we look to 2026, consumers continue to prioritize their health and wellness, and we're well-positioned to meet them – across geographies, across channels, and across life stages."The company issued 2026 guidance of $895-$935 million in consolidated revenue, representing 9-14% growth, with adjusted EBITDA of $174-$181 million. China revenue surged over 56% in 2025 as digital marketing deepened consumer engagement, while Jamieson's quality-focused marketing in Canada continued to outpace the broader vitamins and supplements market.Herbalife (NYSE: HLF) recently reported fourth quarter 2025 net sales of $1.3 billion, up 6.3% year-over-year, with full-year 2025 net sales reaching $5.0 billion. Adjusted EBITDA exceeded guidance for both periods, and the company reduced its total leverage ratio to 2.8x by year-end while generating $333.3 million in net cash from operating activities."We exited 2025 with solid momentum, delivering Q4 and full-year net sales growth and adjusted EBITDA above guidance," said Stephan Gratziani, CEO of Herbalife. "Cristiano Ronaldo's investment in Pro2col reflects our shared ambition to scale personalized nutrition and wellness globally – uniting science, data, AI, innovation, and community to improve the health and performance of millions."Cristiano Ronaldo invested $7.5 million for a 10% equity stake in Herbalife's Pro2col digital health platform, which launched its Beta 2.0 in the U.S., Canada, and Puerto Rico. The company issued 2026 guidance targeting net sales growth of 1-6% and adjusted EBITDA of $670-$710 million.USANA Health Sciences (NYSE: USNA) recently reported fiscal year 2025 net sales of $925.3 million, an 8% increase year-over-year, driven by a full-year contribution from Hiya children's wellness brand and expanding omnichannel distribution. Fourth quarter net sales reached $226.2 million, up 6% year-over-year and sequentially, with adjusted diluted EPS of $0.60 exceeding consensus estimates."We began to see signs of stabilization in active customer counts in our core nutritional business as net sales in this segment increased modestly sequentially, led by growth in key markets including mainland China, the United States and Canada," said Kevin Guest, Chairman and CEO of USANA Health Sciences. "Meanwhile, our omnichannel brands, Hiya and Rise, posted solid year-over-year growth."USANA's Rise Wellness brand tripled its sales in 2025 as distribution expanded into key retail outlets, with net sales outside the core nutritional business rising to 16% of consolidated revenue from approximately 1% in 2024. The company issued 2026 guidance of $925 million-$1.0 billion in net sales.Natural Health Trends (NASDAQ: NHTC) recently announced the repurchase of all 2,935,227 shares held by the George K. Broady family for approximately $5.9 million at $2.00 per share, retiring roughly 25.5% of outstanding shares in a single negotiated transaction. The buyback was executed under the company's previously announced $70 million share repurchase program, with approximately $16 million remaining available for future repurchases."This privately negotiated transaction allows us to efficiently retire a large block of shares in a single, orderly transaction at an attractive price, addressing the perceived stock overhang and significantly reducing our shares outstanding," said Chris Sharng, President of Natural Health Trends.Following the transaction, Natural Health Trends has 8,577,848 shares outstanding and expects annual dividend requirements to decline by approximately $1.2 million. The company is a leading direct-selling and e-commerce wellness products company focused on personal care and nutritional supplements across global markets.CONTINUED… Read this and more news for Doseology at: https://equity-insider.com/2025/12/19/what-comes-after-cigarettes-vapes-and-energy-drinks/CONTACT:
EQUITY INSIDER
info@equity-insider.com
(604) 265-2873DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity-Insider.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). "). This article is being distributed for Maynard Communications ("MAY"), who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Doseology Sciences. Inc. advertising or digital media, but expects to be paid a fee from ("MAY"). There may be 3rd parties who may have shares of Doseology Sciences Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Doseology Sciences Inc., which were purchased as a part of a private placement. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Doseology Sciences Inc.; this is a paid advertisement, we currently own shares of Doseology Sciences Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:https://www.marketreportanalytics.com/reports/low-zero-sugar-beverages-259636https://www.grandviewresearch.com/press-release/global-nicotine-pouches-markethttps://www.insightaceanalytic.com/report/global-functional-beverages-market/1188Logo - https://mma.prnewswire.com/media/2840019/5835646/Equity_Insider_Logo.jpg 



View original content to download multimedia:https://www.prnewswire.com/news-releases/next-generation-platforms-scale-across-energy-wellness-and-smokeless-consumer-segments-302704196.html

Original: Next-Generation Platforms Scale Across Energy, Wellness, and Smokeless Consumer Segments

NMTC : NeuroOne Medical Technologies: Buy Rating Reaffirmed on Strong Revenue Growth and Strategic Partnerships

https://www.tipranks.com/news/ratings/neuroone-medical-technologies-buy-rating-reaffirmed-on-strong-revenue-growth-and-strategic-partnerships-ratings

NMTC NICE MOVE UNDERWAY

NMTC...........................https://stockcharts.com/h-sc/ui?s=NMTC&p=W&b=5&g=0&id=p86431144783

NMTC ON THE MOVE

nmtc.............................................a/h

NMTC - EARNINGS -
https://www.stocktitan.net/news/NMTC/neuro-one-r-reports-third-quarter-fiscal-year-2024-financial-results-faqksv1wj5jc.html

NeuroOne signs distro deal for neuroablation system, brings in more than $5M
AUGUST 5, 2024 BY SEAN WHOOLEY

FacebookXLinkedInShare
NeuroOne_Logo (1)NeuroOne Medical Technologies (Nasdaq:NMTC) announced today that it signed a distribution deal for its OneRF ablation system.

The Eden Prairie, Minnesota-based company signed a non-binding term sheet with an undisclosed global medical technology company. The partnership remains subject to the negotiation and execution of definitive documentation, due diligence and other closing conditions.

NeuroOne’s latest partnership could mirror the one it has with Zimmer Biomet for its Evo sEEG electrodes.

The company’s OneRF system picked up FDA 510(k) clearance in December 2023. Indications cover the creation of radiofrequency (RF) lesions in nervous tissue for functional neurosurgical procedures. This technology uses already-implanted sEEG electrodes to record brain activity and enable the ablation of nervous tissue. It connects to a proprietary radiofrequency (RF) generator. NeuroOne’s electrodes provide a similar function at the subsurface level of the brain compared to cortical electrodes.

NeuroOne also closed a $2.65 million private placement and added $3 million in an additional credit facility.

“Today’s financings, $3 million of which is minimally dilutive to our shareholders, puts our company in a strong position to operate our business and move forward with a potential partnership for our OneRF Ablation System, which we anticipate will close by the end of the third calendar quarter,” Dave Rosa, CEO of NeuroOne, said in a news release.

More about the NeuroOne financings
NeuroOne’s private placement consisted of an aggregate of nearly 3 million shares of common stock, plus warrants to purchase 2.2 million shares of common stock at a purchase price of 90¢ per unit. Each unit consisted of one share of common stock and a warrant to purchase 0.75 shares of common stock.

Warrants have an exercise price of $1.19 per share of common stock. They’re exercisable for a period of three years from the date of issuance. Investors in this placement included current institutional investors and insiders.

The company also secured its $3 million credit line from Growth Opportunity Funding, LLC.

NeuroOne plans to use proceeds from its offering to fund operations, working capital and general corporate purposes. That could include expanding commercialization efforts for the limited OneRF launch. It could also extend to product development for a new ablation indication and completion of the diligence process with a potential strategic partners.

Bounced off the low on 8/5 - has funding and earnings out 8/12 - Got the hospital code and has FDA approval.
Hummmmmmmmmmmmm....... Might get really interesting

NMTC new 52 week low

This might get interesting....

NMTC Neuroone receives FDA 510(k) clearance for the OneRF Ablation System. Stock is low-float and a prospectus was filed in early December so trade appropriately.

Device Classification Name generator, lesion, radiofrequency
510(k) Number K231675
Device Name OneRF Ablation System
Applicant
NeuroOne Medical Technologies Corp.
7599 Anagram Drive
Eden Prairie, MN 55344
Applicant Contact Debra Kridner
Correspondent
Mcra, LLC
803 7th St., NW, 3rd Floor
Washington, DC 20001
Correspondent Contact John Doucet
Regulation Number 882.4400
Classification Product Code
GXD
Subsequent Product Code
GXI
Date Received 06/08/2023
Decision Date 12/06/2023
Decision Substantially Equivalent (SESE)
Regulation Medical Specialty Neurology
510k Review Panel Neurology
Type Traditional
Reviewed by Third Party No
Combination Product No

Get more shares now

NMTC - proprietary assets


$NMTC
_______________________________
Financial Highlights:

Product revenue of $630,000 in Q3 2023, compared to $32,000 in Q3 2022
Collaboration revenue of $1.46 million in first nine months of FY 2023, compared to $6,000 in first nine months of FY 2022
Operating cash burn reduction expected with the completion of development of the OneRF™ Ablation System beginning in Fiscal Q4 2023
Evo® sEEG:

Completed limited launch at target centers by end of July; full launch with Zimmer Biomet expected by end of fiscal fourth quarter
Positive user feedback received on product evaluation forms
Initiation of new sites expected to ramp in fiscal fourth quarter
Received first order for calendar 2024 product supply from Zimmer Biomet
OneRF™Ablation:

Submitted 510(k) to FDA on June 8th
Poster presentation on OneRF Ablation System preclinical study at the Neurological Disorders Summit (NDS 2023) in Italy
Received feedback from FDA regarding 510(k) submission for OneRF Ablation System
Spinal Cord Stimulation Program:

Completed 28 day animal implants of the Company’s thin film spinal cord stimulation paddle electrodes without any adverse events or neurological complications
Filed a non-provisional patent for a novel conformable thin film paddle lead for spinal cord placement
Drug Delivery Program:

Successfully completed proof of concept testing of drug delivery into the brain in a small animal model at the Mayo Clinic in Rochester, Minnesota
OTHER CATALYSTS

1. Disruptive next-generation diagnostic electrodes advancing a new era in neuroscience; foundational technology initially developed in collaboration with Mayo Clinic, a shareholder of the Company.
2. Strategic partnership with Zimmer Biomet (NYSE:ZBH, ~$27B mkt cap) to exclusively commercialize and distribute EVO® diagnostic electrodes; accelerated payment of $3.5 million received in August 2022.
3. Potential to penetrate large disease populations including epilepsy, Parkinson’s disease, and spinal cord stimulation, with total addressable markets of $1+ billion, $5+ billion, and $10+ billion, respectively.
Multi-billion market opportunity for combination devices; potential for technology adaptation and entry into AI and machine learning markets.
Platform technology with licensing potential for applications in urinary incontinence, pain management, hypertension, depression, and other related neurological disorders.
4. Ample capital resources to support upcoming commercial and development catalysts including the commercial launch of the Evo sEEG diagnostic line, and further development of OneRF and a thin-film-based SCS electrode system.
Leadership with deep expertise in medical device technology, marketing, and business development; world-class board of directors; esteemed scientific and physician advisory boards.
______________________________________________________________________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC *** NMTC ***NMTC

NMTC - Technical opinion

$NMTC ****
___________________________________
INDICATOR:

Composite Indicator
Trend Seeker®
BUY
Short Term Indicators
20 Day Moving Average
BUY
20 - 50 Day MACD Oscillator
BUY
20 - 100 Day MACD Oscillator
SELL
20 - 200 Day MACD Oscillator
SELL
20 - Day Average Volume: 201,310 Average: HOLD
source: BarChart.COM --- https://www.barchart.com/stocks/quotes/NMTC/opinion11/08/2023
____________________________
$NMTC *** NMTC *** NMTC *** NMTC *** NMTC *** NMTC ***

$NMTC - PR 11/07/2023

$NMTC
__________________________________________________
Projection -
Potential to penetrate large disease populations including epilepsy, Parkinson’s disease, and spinal cord stimulation, with total addressable markets of $1+ billion, $5+ billion, and $10+ billion, respectively.
Multi-billion market opportunity for combination devices; potential for technology adaptation and entry into AI and machine learning markets.
Platform technology with licensing potential for applications in urinary incontinence, pain management, hypertension, depression, and other related neurological disorders.
Ample capital resources to support upcoming commercial and development catalysts including the commercial launch of the Evo sEEG diagnostic line, and further development of OneRF and a thin-film-based SCS electrode system.
Leadership with deep expertise in medical device technology, marketing, and business development; world-class board of directors; esteemed scientific and physician advisory boards.
____________________________________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC. *** $NMTC *** $NMTC *** $NMTC

8K Out - filed 11/07/2023


$NMTC
_______________________________
discussion:
Dave Rosa, CEO of NeuroOne, commented, “We remain bullish on the potential for this technology to cause a paradigm shift in how patients are treated in ablation procedures. The potential to reduce hospital stays, additional procedures, complications and cost gives us confidence that this will have a meaningful impact in the market. We hope to complete discussions with the FDA in the near future as we prepare for a targeted commercial launch in the first half of 2024.”[/I]
___________________________________
Current:
Float: 7,976,291 shares available to trade
_______________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC *** NMTC *** NMTC ***

***News out NMTC

$NMTC - news out FDA response

_news today_____________________________
NeuroOne® Provides Progress Update on FDA 510(k) Submission for OneRF™ Ablation System
November 07 2023 - 08:00AM
GlobeNewswire Inc.

_____________________________
Current shares -
Float: 7,976,291 shares available to trade
_______________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC *** NMTC. *** NMTC

$NMTC - up 5% from bottom


$NMTC - feature

$NMTC - MACD rising above 9D-MA
_____________________
Total shares outstanding ****** 23,919,184 (11/03/2023)
$NMTC



NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode in Robotic #Neurosurgery: Evo sEEG electrode used with Zimmer Biomet’s ROSA One® Brain during procedure at @ClevelandClinic.

Read here: https://t.co/5hLL0U97Od$NMTC #N1MTC pic.twitter.com/Rj21O8388A
— NeuroOne Medical Technologies Corporation (@N1MTC) May 17, 2023

--- Full Profile Here: https://insiderfinancial.com/newalert
[Operating cash burn reduction expected with the completion of development of the OneRF™ Ablation System beginning in Fiscal Q4 2023].
__________________________________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC

$NMTC - feature

$NMTC - accumulation
_____________________
current float: ****** 7,976,291 (11/03/2023)
$NMTC

Full Profile Here: https://insiderfinancial.com/newalert
[Operating cash burn reduction expected with the completion of development of the OneRF™ Ablation System beginning in Fiscal Q4 2023].
__________________________________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC

$NMTC - re 'Going Higher'
_____________________

$NMTC

STRATEGIC PARTNERSHIP WITH ZIMMER BIOMET (NYSE:ZBH, ~$27B MKT CAP) TO EXCLUSIVELY COMMERCIALIZE AND DISTRIBUTE EVO® DIAGNOSTIC ELECTRODES; ACCELERATED PAYMENT OF $3.5 MILLION RECEIVED IN AUGUST 2022

Operating cash burn reduction expected with the completion of development of the OneRF™ Ablation System beginning in Fiscal Q4 2023.
__________________________________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC

NMTC - catalysts


$NMTC
_______________________________
Financial Highlights:

Product revenue of $630,000 in Q3 2023, compared to $32,000 in Q3 2022
Collaboration revenue of $1.46 million in first nine months of FY 2023, compared to $6,000 in first nine months of FY 2022
Operating cash burn reduction expected with the completion of development of the OneRF™ Ablation System beginning in Fiscal Q4 2023
Evo® sEEG:

Completed limited launch at target centers by end of July; full launch with Zimmer Biomet expected by end of fiscal fourth quarter
Positive user feedback received on product evaluation forms
Initiation of new sites expected to ramp in fiscal fourth quarter
Received first order for calendar 2024 product supply from Zimmer Biomet
OneRF™Ablation:

Submitted 510(k) to FDA on June 8th
Poster presentation on OneRF Ablation System preclinical study at the Neurological Disorders Summit (NDS 2023) in Italy
Received feedback from FDA regarding 510(k) submission for OneRF Ablation System
Spinal Cord Stimulation Program:

Completed 28 day animal implants of the Company’s thin film spinal cord stimulation paddle electrodes without any adverse events or neurological complications
Filed a non-provisional patent for a novel conformable thin film paddle lead for spinal cord placement
Drug Delivery Program:

Successfully completed proof of concept testing of drug delivery into the brain in a small animal model at the Mayo Clinic in Rochester, Minnesota
OTHER CATALYSTS

Disruptive next-generation diagnostic electrodes advancing a new era in neuroscience; foundational technology initially developed in collaboration with Mayo Clinic, a shareholder of the Company.
Strategic partnership with Zimmer Biomet (NYSE:ZBH, ~$27B mkt cap) to exclusively commercialize and distribute EVO® diagnostic electrodes; accelerated payment of $3.5 million received in August 2022.
Potential to penetrate large disease populations including epilepsy, Parkinson’s disease, and spinal cord stimulation, with total addressable markets of $1+ billion, $5+ billion, and $10+ billion, respectively.
Multi-billion market opportunity for combination devices; potential for technology adaptation and entry into AI and machine learning markets.
Platform technology with licensing potential for applications in urinary incontinence, pain management, hypertension, depression, and other related neurological disorders.
Ample capital resources to support upcoming commercial and development catalysts including the commercial launch of the Evo sEEG diagnostic line, and further development of OneRF and a thin-film-based SCS electrode system.
Leadership with deep expertise in medical device technology, marketing, and business development; world-class board of directors; esteemed scientific and physician advisory boards.
______________________________________________________________________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC

NMTC - Debt to equity


$NMTC
_______________________________
Current: debt/equity: 0.31
Total Assets: *** $5,758,124 - per latest 10K (08/14/2023)
Total Liabilities * $1,836,826 - " - " - " - " - " - (08/14/2023)
https://www.otcmarkets.com/stock/NMTC/disclosure
_______________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC

NMTC - low floater - structure

$NMTC
_______________________________
Current:
Float: 7,976,291 shares available to trade
_______________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC *** $NMTC

NMTC - low floater - structure

$NMTC
_______________________________
Current:
Float: 7,976,291 shares available to trade
_______________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC ***

NMTC share structure

$NMTC
_______________________________
Current:
Held at DTC: 13,732,171 shares
_______________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC ***

NMTC share structure

NMTC
_______________________________
current:
O/S: 23,919,184 shares
_______________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC

NMTC partnership
___________________________
Highlights:
-- STRATEGIC PARTNERSHIP WITH ZIMMER BIOMET (NYSE:ZBH, ~$27B MKT CAP) TO EXCLUSIVELY COMMERCIALIZE AND DISTRIBUTE EVO® DIAGNOSTIC ELECTRODES; ACCELERATED PAYMENT OF $3.5 MILLION RECEIVED IN AUGUST 2022
-- NMTC HAS NO DEBT OUTSTANDING AS OF JUNE 30, 2023
-- PRODUCT REVENUE OF $630,000 IN Q3 2023, COMPARED TO $32,000 IN Q3 2022

_______________________________________________________________________________
$NMTC *** NMTC *** NMTC *** NMTC *** NMTC *** NMTC

NMTC ratings

NMTC
________________________________
Barchart Opinion
INDICATOR
Opinion Strength & Direction ***BUY
Composite Indicator
Trend Seeker® ***BUY
_________________________
Short Term Indicators
20 Day Moving Average ***BUY
_________________________________________
_______________________________________________________________________________
$NMTC *** NMTC *** NMTC *** NMTC *** NMTC *** NMTC

$NMTC treats

_______________
NMTC
_______________________________

Financial Highlights

Product revenue of $630,000 in Q3 2023, compared to $32,000 in Q3 2022
Collaboration revenue of $1.46 million in first nine months of FY 2023, compared to $6,000 in first nine months of FY 2022
Operating cash burn reduction expected with the completion of development of the OneRF™ Ablation System beginning in Fiscal Q4 2023
Evo® sEEG:

Completed limited launch at target centers by end of July; full launch with Zimmer Biomet expected by end of fiscal fourth quarter
Positive user feedback received on product evaluation forms
Initiation of new sites expected to ramp in fiscal fourth quarter
Received first order for calendar 2024 product supply from Zimmer Biomet
OneRF™Ablation:

Submitted 510(k) to FDA on June 8th
Poster presentation on OneRF Ablation System preclinical study at the Neurological Disorders Summit (NDS 2023) in Italy
Received feedback from FDA regarding 510(k) submission for OneRF Ablation System
Spinal Cord Stimulation Program:

Completed 28 day animal implants of the Company’s thin film spinal cord stimulation paddle electrodes without any adverse events or neurological complications
Filed a non-provisional patent for a novel conformable thin film paddle lead for spinal cord placement
Drug Delivery Program:

Successfully completed proof of concept testing of drug delivery into the brain in a small animal model at the Mayo Clinic in Rochester, Minnesota
_______________________________________________________________________________
$NMTC *** NMTC *** NMTC *** NMTC *** NMTC *** NMTC

NMTC partnership
___________________________
Highlights:
-- STRATEGIC PARTNERSHIP WITH ZIMMER BIOMET (NYSE:ZBH, ~$27B MKT CAP) TO EXCLUSIVELY COMMERCIALIZE AND DISTRIBUTE EVO® DIAGNOSTIC ELECTRODES; ACCELERATED PAYMENT OF $3.5 MILLION RECEIVED IN AUGUST 2022
-- NMTC HAS NO DEBT OUTSTANDING AS OF JUNE 30, 2023
-- PRODUCT REVENUE OF $630,000 IN Q3 2023, COMPARED TO $32,000 IN Q3 2022

_______________________________________________________________________________
$NMTC *** NMTC *** NMTC *** NMTC *** NMTC *** NMTC

$NMTC - Monday 10/30/2023 mention

NMTC ________________
______________

_______________________________________________________________________________
$NMTC *** $NMTC *** $NMTC *** NMTC *** $NMTC *** $NMTC

NMTC news ....

$NMTC
___________________________
CATALYSTS:

1. Disruptive next-generation diagnostic electrodes advancing a new era in neuroscience; foundational technology initially developed in collaboration with Mayo Clinic, a shareholder of the Company.
2. Strategic partnership with Zimmer Biomet (NYSE:ZBH, ~$27B mkt cap) to exclusively commercialize and distribute EVO® diagnostic electrodes; accelerated payment of $3.5 million received in August 2022.
3. Potential to penetrate large disease populations including epilepsy, Parkinson’s disease, and spinal cord stimulation, with total addressable markets of $1+ billion, $5+ billion, and $10+ billion, respectively.
4. Multi-billion market opportunity for combination devices; potential for technology adaptation and entry into AI and machine learning markets.
5. Platform technology with licensing potential for applications in urinary incontinence, pain management, hypertension, depression, and other related neurological disorders.
6. Ample capital resources to support upcoming commercial and development catalysts including the commercial launch of the Evo sEEG diagnostic line, and further development of OneRF and a thin-film-based SCS electrode system.
Leadership with deep expertise in medical device technology, marketing, and business development; world-class board of directors; esteemed scientific and physician advisory boards.
_______________________________________________________________________________
$NMTC *** $NMTC *** $NMTC *** NMTC *** $NMTC *** $NMTC

NMTC Update

$NMTC
_____________________
Financial Highlights

Product revenue of $630,000 in Q3 2023, compared to $32,000 in Q3 2022
Collaboration revenue of $1.46 million in first nine months of FY 2023, compared to $6,000 in first nine months of FY 2022
Operating cash burn reduction expected with the completion of development of the OneRF™ Ablation System beginning in Fiscal Q4 2023.
__________________________________________________
$NMTC *** $NMTC *** $NMTC *** $NMTC

NMTC recent profile

________________________________
NMTC HAS NO DEBT OUTSTANDING AS OF JUNE 30, 2023
PRODUCT REVENUE OF $630,000 IN Q3 2023, COMPARED TO $32,000 IN Q3 2022
___________________________
$NMTC

I bought 900 shares right before closing and it didn’t show them in trades.

NMTC.......................https://stockcharts.com/h-sc/ui?s=NMTC&p=W&b=5&g=0&id=p86431144783

2.10 right around the corner

Tapped this baby again

$NMTC loading up this week! :)

Up 8% on 2X average daily volume. I like it.

Nice green start here.

$NMTC

it seems this this has become a trading stock. I'm holding

Impressive run over the short term. Better than expected.

Highlights from the Neuralink presentation yesterday.

Quarter-sized implant with 64 "hairs".
Drill holes.
Remove quarter-sized section of skull.
Insert 64 "hairs" / electrodes into the brain.
Insert quarter-size implant into the section of removed skull bone.
Seal of skin and viola, you're brain now has blue tooth.

Up 12% early. Let's see if it holds.

Elon's Neuralink is now "ready" for humans. Elon tweeted the news last night. Didn't get any "pin action" from Neuralink's yearly presentation last year. Maybe this year is different? 20% bump today, perhaps?

anyone out there???

Huge coverage on Fox Business this AM - love what the company does. just took a small position today.

FDA 501(k) clearance for 30 day use of the EVO sEEG system is huge news, and takes the shackles off of Zimmer Biomet to market this product.

The share price drop, in the face of this great news, is perplexing, but will likely be followed by a sharp rebound once this news is fully processed by the market.